Management of Overactive Bladder Symptoms After Radical Prostatectomy
Purpose of Review
Post-prostatectomy overactive bladder (OAB) is a common and challenging condition to manage. The aim of the present report was to review the recent evidences regarding OAB symptoms that develop in men after prostatectomy and how to manage them.
The prevalence of OAB after radical prostatectomy may range from 15.2 to 37.8%. Recent studies have highlighted the role of the urethrogenic mechanism (facilitation of the urethrovesical reflex due to stress urinary incontinence (SUI)) in the genesis of post-prostatectomy OAB in a significant proportion of patients. Several other pathophysiological factors such as iatrogenic decentralization of the bladder, defunctionalized bladder due to severe SUI, detrusor underactivity, or bladder outlet obstruction might be involved. The evaluation should aim to identify the underlying mechanism to tailor the treatment, which could range from SUI surgery, to fixing a urethral stricture, improving bladder emptying or using the conventional spectrum of OAB therapies. There is a paucity of data for OAB therapies specific to post-prostatectomy patients, with the exception of solifenacin, tolterodine, and botulinum toxin. There is currently no data on how preoperative management or surgical technique may prevent post-prostatectomy OAB.
Keywords(MeSH) Urinary bladder Overactive Prostatic neoplasms Urinary incontinence Radical prostatectomy
Compliance with Ethical Standards
Conflicts of Interest
Benoit Peyronnet is a consultant for Allergan, Medtronic, Astellas and Boston Scientific, and an investigator for Ipsen.
Benjamin Brucker is a consultant for Allergan, Watkins Conti, Avadel, Serenity, and an investigator for Ipsen and Medtronic.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.• Matsukawa Y, Yoshino Y, Ishida S, et al. De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy. Neurourol Urodyn. 2018. https://doi.org/10.1002/nau.23556 Prospective series identifying low preoperative maximum urethral closure pressure (MUCP) and greater decrease in MUCP postoperatively as significant predictors of urgency after radical prostatectomy strengthening the idea of an urethrogenic mechanism in the pathophysiology of post-prostatectomy OAB. CrossRefGoogle Scholar
- 8.• Hosier GW, Tennankore KK, Himmelman JG, Gajewski J, Cox AR. Overactive bladder and Storage Lower Urinary Tract Symptoms Following Radical Prostatectomy. Urology. 2016;94:193–7 Retrospective series highlighting adjuvant or salvage radiotherapy as a major risk factor of post-prostatectomy OAB. CrossRefGoogle Scholar
- 9.Aning JJ, MacKenzie KR, Fabricius M, et al. Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. Urol Oncol. 2018; in press.Google Scholar
- 14.• Pastore AL, Palleschi G, Illiano E, Zucchi A, Carbone A, Costantini E. The role of detrusor overactivity in urinary incontinence after radical prostatectomy: a systematic review. Minerva Urol Nefrol. 2017;69(3):234–41 Systematic review reporting a prevalence of detrusor overactivity (DO) after radical prostatectomy ranging from 3 to 63% and identifying preoperative DO as the main risk factor of postoperative DO. PubMedGoogle Scholar
- 26.•• Haga N, Ogawa S, Yabe M, et al. Association between postoperative pelvic anatomic features on magnetic resonance imaging and lower tract urinary symptoms after radical prostatectomy. Urology. 2014;84(3):642–9 Series reporting an association between presence of urine in proximal urethra at rest on postoperative MRI and urgency after radical prostatectomy strengthening the idea of an urethrogenic mechanism in the pathophysiology of post-prostatectomy OAB. CrossRefGoogle Scholar
- 28.• Afraa TA, Campeau L, Mahfouz W, Corcos J. Urodynamic parameters evolution after artificial urinary sphincter implantation for post-radical prostatectomy incontinence with concomitant bladder dysfunction. Can J Urol. 2011;18(3):5695–8 Retrospective series showing complete resolution of detrusor overactivity and impaired bladder compliance after artificial urinary sphincter implantation in a vast majority of patients with post-prostatectomy incontinence suggesting artifactual defunctionalized bladder as an explanation of these urodynamic findings. PubMedGoogle Scholar
- 32.Kim DK. Origin of urgency symptom in underactive bladder: commentary on “Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment”. 2015;Int Neurourol J, 19(4):293–4.Google Scholar
- 34.• Jarosek SL, Virnig BA, Chu H, Elliott SP. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol. 2015;67(2):273–80 Population-based study showing a cumulative prevalence of 20.3% of urethral stricture 10 years after radical prostatectomy. CrossRefGoogle Scholar
- 40.Bill-Axelson A, Garmo H, Holmberg L, Johansson JE, Adami HO, Steineck G, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013;64(6):920–8.CrossRefGoogle Scholar
- 45.Tse V, King J, Dowling C, English S, Gray K, Millard R, et al. Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder. BJU Int. 2016;117(1):34–47.CrossRefGoogle Scholar
- 46.• Tienforti D, Sacco E, Marangi F, et al. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. BJU Int. 2012;110(7):1004–10 Randomized controlled trial evidencing significant reduction of OAB symptoms at 3 and 6 months with a structured program of pelvic floor muscle training + biofeedback. CrossRefGoogle Scholar
- 47.• Lai HH, Boone TB. Implantation of artificial urinary sphincter in patients with post-prostatectomy incontinence, and preoperative overactive bladder and mixed symptoms. J Urol. 2011;185(6):2254–9 Retrospective series reporting complete resolution of OAB symptoms in 29% of patients with mixed urinary incontinence after radical prostatectomy. CrossRefGoogle Scholar
- 53.• Cornu JN, Merlet B, Ciofu C, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol. 2011;59(1):148–54 Placebo controlled randomized trial demonstrating efficacy of duloxetine in post-prostatectomy stress urinary incontinence but with no assessment of OAB symptoms. CrossRefGoogle Scholar
- 56.Burkhard F, Bosch J, Cruz F, et al. EAU guidelines on urinary incontinence 2018. Available at: http://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urinary-Incontinence-2018-large-text.pdf.
- 65.• Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int. 2015;116 Suppl 3:61–5 Only published series assessing a third-line OAB therapy in the post-prostatectomy setting and showing 45% of urgency incontinence resolution after onabotulinum toxin A intradetrusor injections. CrossRefGoogle Scholar
- 66.Shim M, Kim J, Park S, Choi SK, Lee SM, Huh KO, et al. The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radicalprostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology. 2015;85(5):1123–9.CrossRefGoogle Scholar
- 67.• Bianco FJ, Albala DM, Belkoff LH, et al. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. J Urol. 2015;193(4):1305–10 Large phase 4 randomized placebo controlled trial showing earlier return to continence after radical prostatectomy with solifenacin 5 mg. CrossRefGoogle Scholar
- 68.Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S, Milsom I, et al. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial. Int J Clin Pract. 2014;68(8):972–85.CrossRefGoogle Scholar